Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

This morning, Michael Clayman, M.D., CEO of Flexion Therapeutics (Nasdaq:  FLXN), appeared live on Fox Business News to talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM (FX006) which is being evaluated as a potential new therapy for OA related knee pain.  A link to Mike’s interview can be found below:

http://finance.yahoo.com/video/developing-alternatives-opioids-relieve-pain-130004965.html